| Literature DB >> 35620094 |
Xiao-Fang Liu1,2, Jun-Xiao Wang1, Xin-Ai Chen1,2, Yu Liu3, Yong-Quan Li1,2.
Abstract
The emergence of drug resistance highlights the importance of new drug discovery. Microbial secondary metabolites encoded in biosynthetic gene clusters (BGCs) are a prolific source of drugs, whereas most of these BGCs are cryptic. Thus, taking strategies to activate these cryptic BGCs is of great importance for potential drug discovery. In this work, three novel pentangular polyphenols lanthomicin A-C were identified by activating a cryptic aromatic polyketide BGC through promoter engineering combined with optimization of fermentation conditions. We further confirmed the involvement of lanthomicin (ltm) BGC in biosynthesis by CRISPR-Cpf1-assisted gene editing. Based on functional analysis of homologous genes, a putative biosynthetic pathway was proposed for the three lanthomicins. Particularly, lanthomicin A showed antiproliferative activity with IC50 0.17 μM for lung cancer cell line A-549. The discovery of lanthomicins brings new members to the pentangular polyphenol subclade of aromatic polyketide and demonstrates the potential of Streptomyces as a source for drug discovery.Entities:
Keywords: CRISPR-Cpf1; Streptomyces chattanoogensis L10; antiproliferative activity; cryptic gene cluster; lanthomicin
Year: 2022 PMID: 35620094 PMCID: PMC9127795 DOI: 10.3389/fmicb.2022.902990
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Figure 1Comparative analysis of the lanthomicin biosynthetic gene cluster. (A) Examples of compounds belong to the pentangular polyphenol subfamily. (B) The maximum likelihood tree of LtmB with homologous KSβ proteins from the well-studied pentangular polyphenol clusters. These KSβ units could be divided into four groups according to the carbon chain length of their products. (C) ltm cluster was indicated by comparison with xan and arx clusters. The operons for promoter engineering were also indicated in the figure.
Deduced functions of genes in the lanthomicin biosynthesis gene cluster and protein homologs annotation.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| ORF11 | 62 | Transposase | WP_161968789.1 | 69 | ||
| LtmP1 | 403 | Cytochrome P450 | WP_137814202.1 | 83 | XanO2 | 35/52 |
| LtmO | 620 | Asparagine synthase | WP_137814203.1 | 85 | XanA, Arx5 | 56/67, 44/58 |
| LtmMT1 | 328 | O-methyltransferase | WP_107082228.1 | 76 | Arx6 | 39/58 |
| LtmGT | 354 | Glycosyltransferase | WP_137814140.1 | 76 | XanG, Arx3 | 55/66, 42/58 |
| LtmF1 | 208 | 3-oxoacyl-ACP reductase | WP_137814141.1 | 86 | XanS2, Arx4 | 53/64, 55/66 |
| LtmD1 | 111 | Cyclase | WP_137814142.1 | 87 | XanC3, Arx14 | 67/82, 80/92 |
| LtmD2 | 145 | Cyclase | WP_137814143.1 | 82 | XanC2, Arx15 | 68/79, 70/76 |
| LtmA | 422 | Beta-ketoacyl synthase alpha | WP_137814144.1 | 90 | XanF, Arx16 | 80/88, 78/87 |
| LtmB | 397 | Ketosynthase chain-length factor | WP_137814129.1 | 87 | XanE, Arx17 | 73/80, 76/83 |
| LtmC | 84 | Acyl carrier protein | WP_137814128.1 | 72 | XanD, Arx18 | 40/60, 51/73 |
| LtmD3 | 152 | Cyclase | WP_137814127.1 | 87 | XanC1, Arx19 | 65/76, 70/82 |
| LtmE | 153 | Monooxygenase | WP_049718470.1 | 79 | XanO8, Arx20 | 66/77, 64/73 |
| LtmF2 | 250 | 3-oxoacyl-ACP reductase | WP_137814126.1 | 85 | XanZ3, Arx21 | 65/82, 64/78 |
| LtmG1 | 108 | Monooxygenase | WP_116198857.1 | 86 | XanO7, Arx22 | 58/74, 67/80 |
| LtmG2 | 92 | Monooxygenase | WP_137814125.1 | 84 | XanO6, Arx23 | 62/72, 66/76 |
| LtmH1 | 571 | carboxyl transferase alpha | WP_125308160.1 | 77 | XanB3 | 67/76 |
| LtmH2 | 174 | biotin carboxyl carrier protein | WP_137814199.1 | 76 | XanB2, Arx35 | 53/60, 49/62 |
| LtmH3 | 469 | biotin carboxylase | WP_137814198.1 | 88 | XanB1 | 74/83 |
| LtmR1 | 613 | SARP family transcriptional regulator | WP_198535620.1 | 73 | ||
| LtmI | 540 | FAD-dependent monooxygenase | WP_200827518.1 | 74 | XanO5, Arx10 | 45/58, 41/57 |
| LtmT | 477 | MFS transporter | WP_137814146.1 | 75 | ||
| LtmR2 | 228 | TetR family transcriptional regulator | WP_158879437.1 | 86 | ||
| LtmJ | 149 | Monooxygenase | WP_043782530.1 | 78 | XanO10, Arx25 | 72/81, 63/78 |
| LtmK | 292 | Dehydrogenase | WP_137814130.1 | 79 | XanS1, Arx13 | 53/67, 50/63 |
| LtmD4 | 128 | CurD-like protein | WP_049718476.1 | 86 | XanV, Arx26 | 76/87, 80/89 |
| LtmL | 493 | Peptide permease | KNB50326.1 | 73 | XanQ, Arx28 | 52/68, 49/64 |
| LtmG3 | 541 | FAD-dependent monooxygenase | WP_137814132.1 | 89 | XanO4, Arx30 | 70/82, 64/77 |
| LtmN | 286 | Reductase | WP_137814133.1 | 88 | XanZ1, Arx33 | 57/70, 45/64 |
| LtmG4 | 421 | FAD-dependent monooxygenase | WP_192909516.1 | 83 | XanO4 | 26/39 |
| LtmF3 | 245 | 3-oxoacyl-ACP reductase | WP_137814135.1 | 88 | XanZ4, Arx27 | 65/77, 67/79 |
| LtmMT2 | 336 | Methyltransferase | WP_137814136.1 | 86 | XanM3 | 68/80 |
| LtmD5 | 122 | CurD-like protein | WP_137814137.1 | 83 | XanT, Arx29 | 63/79, 61/75 |
| LtmMT3 | 351 | Methyltransferase | WP_162834049.1 | 80 | XanM3 | 45/62 |
| LtmP2 | 467 | Cytochrome P450 | WP_043782514.1 | 82 | XanO2 | 39/55 |
| ORF47 | 191 | Transcriptional regulator NovG | GCB88085.1 | 70 |
Figure 2Activation of cryptic lanthomicin gene cluster by promoter knock-in and changing cultivating environment. (A) Lanthomicins were produced on a solid YMG plate by overexpression of ltmF1-D3 cassette. (B) Schematic of a promoter replacement strategy that a Km-kasO*p cassette was inserted upstream of the ltmF1 gene and replaced the native promoter by homologous recombination. (C) HPLC analysis of the metabolites from different strains (UV at 480 nm): (I) S. chattanoogensis L10; (II) S. chattanoogensis L10-OE-R1; (III) S. chattanoogensis L10-ΔR2; (IV) S. chattanoogensis L10-OE-F1D3; (V) S. chattanoogensis XF1; (VI) S. chattanoogensis XF1 (changing fermentation environment); (VII) isolated lanthomicin A; (VIII) isolated lanthomicin B; and (IX) isolated lanthomicin C.
Figure 3Quantitative real-time PCR experiment. By promoter replacement, gene transcription levels from ltmF1 to ltmH3 in S. chattanoogensis XF1 were significantly upregulated, while genes distributed at two sides were almost the same transcriptional levels as the control strain L10. Fold change was indicated as log2 (XF1/L10).
Figure 4Confirmation of lanthomicins biosynthesis gene cluster ltm by the CRISPR-Cpf1-based gene-editing system. (A) Transformation efficiency was evaluated by counting the transformant number per 106 viable spores. (B) HPLC analysis of lanthomicin B production from ltmA deletion and complement strains (UV at 480 nm): (I) S. chattanoogensis XF1; (II) S. chattanoogensis XF1-ΔA; (III) S. chattanoogensis XF1-ΔA-OE-A; and (IV) isolated lanthomicin B.
Figure 5Planar structures of lanthomicin A-C. Key COSY, HMBC, and NOESY correlations of lanthomicin A–C are indicated.
Antitumor activity of lanthomicins.
|
| ||||
|---|---|---|---|---|
|
|
|
|
| |
| A-549 (lung) | 0.02 | 0.17 | >100 | >100 |
| MCF-7 (breast) | 0.62 | 5.98 | >100 | >100 |
| HepG2 (liver) | 4.38 | 34.34 | >100 | >100 |
| HCT-116 (colon) | 10.58 | 82.27 | >100 | >100 |
Figure 6The proposed biosynthetic pathway of lanthomicins.